Analyst Price Targets — ICLR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 23, 2026 9:40 am | David Windley | Jefferies | $135.00 | $99.70 | TheFly | Icon upgraded to Buy from Hold at Jefferies |
| February 17, 2026 9:58 am | Jamie Clark | Redburn Partners | $100.00 | $93.00 | TheFly | Icon downgraded to Neutral from Buy at Rothschild & Co Redburn |
| February 13, 2026 2:21 pm | — | Robert W. Baird | $119.00 | $91.63 | TheFly | Icon price target lowered to $119 from $217 at Baird |
| February 12, 2026 1:58 pm | Sean Dodge | BMO Capital | $100.00 | $84.63 | TheFly | Icon price target lowered to $100 from $175 at BMO Capital |
| February 12, 2026 1:25 pm | Michael Cherny | Leerink Partners | $105.00 | $83.90 | TheFly | Icon downgraded to Market Perform from Outperform at Leerink |
| January 9, 2026 1:33 pm | — | Robert W. Baird | $217.00 | $187.66 | TheFly | Icon price target lowered to $217 from $220 at Baird |
| January 9, 2026 12:09 pm | — | Mizuho Securities | $216.00 | $188.22 | TheFly | Icon price target lowered to $216 from $225 at Mizuho |
| January 8, 2026 10:14 am | — | Truist Financial | $222.00 | $202.92 | TheFly | Icon downgraded to Hold from Buy at Truist |
| December 15, 2025 10:54 am | Luke Sergott | Barclays | $200.00 | $186.71 | TheFly | Icon price target raised to $200 from $185 at Barclays |
| October 24, 2025 12:13 pm | — | UBS | $220.00 | $175.87 | TheFly | Icon price target lowered to $220 from $240 at UBS |
Latest News for ICLR
New York, New York--(Newsfile Corp. - March 2, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into ICON Public Limited Company ("ICON Public Limited Company") (NASDAQ: ICLR) concerning potential violations of the federal securities laws. The magnitude of the single-day decline wiped out billions of dollars of shareholder value and represented one of the largest percentage drops in…
Artisan Partners Limited Partnership lowered its position in shares of Icon Plc (NASDAQ: ICLR) by 1.6% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,071,360 shares of the medical research company's stock after selling 113,510 shares during the quarter. Icon accounts
NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ICON plc ("ICON" or the "Company") (NASDAQ: ICLR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
MILWAUKEE, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating possible securities fraud claims against ICON (NASDAQ: ICLR). The investigation results from inaccurate statements ICON may have made regarding its financial statements, business operations and prospects.
LOS ANGELES, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ICON Public Limited Company (“ICON” or “the Company”) (NASDAQ: ICLR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for ICLR.
Senate Trading
No Senate trades found for ICLR.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.